Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Angiography-Derived Index of Microcirculatory Resistance (Angio-IMR) Is Associated With Doppler-Derived Hyperemic Microvascular Resistance.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Implementation of Evidence-Based, Person-Centered Alternative Delivery Models for Cardiac Rehabilitation in a Rural and Remote Population: The Country Heart Attack Prevention (CHAP) Project.

Heart, lung & circulation·2026
Same author

Characteristics, readmission patterns and trends in hospitalisations for chronic coronary disease in Western Australia, 2005 to 2022.

International journal of cardiology·2026
Same author

Allergy-Associated Acute Coronary Syndromes: Therapeutic Framework for Kounis Syndrome.

JACC. Case reports·2026
Same author

Cardiac resynchronization therapy with or without atrioventricular node ablation in atrial fibrillation: the CAAN-AF trial.

European heart journal·2026
Same author

Beta-blocker therapy and all-cause mortality after a coronary event: A matched nested case-control study using the Victorian Cardiac Outcomes Registry linked data.

Current problems in cardiology·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Jul 2, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

急性心筋梗塞は急性心筋梗塞である.

Harvey D White1, Derek P Chew

  • 1Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.

Lancet (London, England)
|August 19, 2008
PubMed
まとめ
この要約は機械生成です。

近代的な急性心筋梗塞 (MI) 管理は,抗血栓療法と適時再注血により,死亡率を大幅に低下させました. すべての患者にエビデンスを適用し,世界的な心血管疾患の傾向に対処するには,依然として課題が残っています.

さらに関連する動画

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery
08:38

Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery

Published on: August 16, 2019

関連する実験動画

Last Updated: Jul 2, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
09:05

Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice

Published on: May 4, 2015

Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery
08:38

Murine Myocardial Infarction Model using Permanent Ligation of Left Anterior Descending Coronary Artery

Published on: August 16, 2019

科学分野:

  • 心臓病学 心臓病学
  • クリニカル・メディシン 臨床医学
  • 証拠に基づいた実践

背景:

  • 急性心筋梗塞 (MI) の管理は30年以上にわたって進化し,死亡率と罹患率を大幅に低下させました.
  • 治療の成功は,抗血栓治療と適切な再注射戦略 (STEMIのPCIまたはフィブリノリシス,NSTEMIの侵襲的ケア) を統合することに依存しています.
  • リスクの階層化と最適化されたケアシステムは,効果的なMI管理に不可欠です.

研究 の 目的:

  • 心筋梗塞の病理生理学,診断,リスク階層化,および管理について議論します.
  • 臨床的証拠に基づいて,心筋梗塞の治療の進化を強調する.
  • 多様な患者集団と世界的な健康動向への証拠の翻訳における課題に取り組む.

主な方法:

  • 過去30年にわたる研究から得られた臨床的証拠のレビュー.
  • トロポニンアッセイとMIの普遍的な定義を含む診断の進歩の分析.
  • 抗血栓性療法,再注射,再血管化を含む治療戦略の議論.

主要な成果:

  • 急性心筋梗塞に関連した死亡率と罹患率の大幅な減少.
  • トロポニンアッセイと普遍的分類を通じてMIの病理生理学的理解を深めた.
  • 出血や介護の格差などの有害事象に対する意識の増大.

結論:

  • 効果的なMI管理には,抗血栓性療法と適時な再注血およびリスク分層化が統合されています.
  • 課題には,過小評価されているグループ (高齢者,腎不全) のための公正な証拠翻訳と,世界的な健康のシフトが含まれています.
  • 糖尿病,肥満,開発途上国における心血管疾患の増加により,医療システムに対する将来の要求は増加するでしょう.